Table S3. Statistical analysis of expression of activation markers and apoptosis in T cells stimulated with anti-CD3/CD28 antibodies (aCD3/CD28) alone or in combination with IFN-α or IFN-γ in breast cancer patients versus healthy controls.

A. P-values and estimated differences with 95% CI from two-sided Mann Whitney test to compare single marker data from breast cancer patients and healthy controls.

Marker	p-values and estimated differences with 95% CI under each stimulation condition						Sample Size	
	aCD3/CD28		aCD3/CD28 +IFN-α		aCD3/CD28 +IFN-γ		H	BC
CD25	0.004	10 (2 to 42)	0.020	20.5 (3 to 36)	0.185	13.5 (-4 to 33)	8	8
HLA-DR	0.018	6.5 (1 to 16)	0.109	8 (-1 to 20)	0.486	3 (-11 to 16)	8	8
CD54	0.108	17 (-1 to 42)	0.016	28.5 (6 to 46)	0.137	14 (-6 to 38)	8	8
CD95	0.848	0 (-2 to 3)	0.077	10 (-1 to 22)	0.061	11 (-2 to 21)	8	8
Anx Viv	0.087	-6 (-17 to 0)	0.818	-2 (-20 to 23)	0.363	-4.5 (-23 to 16)	8	8

B. Correlation of activation markers in T cells stimulated with anti-CD3 anti-CD28 antibodies alone or in combination with IFN-α or IFN-γ.

Pairs of Markers	Correlation coefficient under each stimulation condition		
	aCD3/CD28	aCD3/CD28 +IFN-α	aCD3/CD28 +IFN-γ
CD25 & CD54	0.94	0.92	0.92
CD25 & CD95	0.19	0.74	0.81
CD25 & HLA-DR	0.90	0.65	0.64
CD54 & CD95	0.35	0.75	0.86
CD54 & HLA-DR	0.87	0.60	0.51
CD95 &HLA-DR	0.13	0.59	0.56

C. P-values from multivariate analysis of CD25, CD54, HLA-DR and CD95 expression in T cells from breast cancer patients versus healthy controls using principal components analysis followed by two-sided Mann-Whitney test along the first principal component.

p-values under each stimulation condition			Sample Size	
aCD3/CD28	aCD3/CD28 +IFN-α	aCD3/CD28 +IFN-γ	H	BC
0.021	0.038	0.083	8	8